ERBB2 and neoplasm: These efforts resulted in the development of anti-HER2 affibody molecule ZHER2:V2 labelled with the cytotoxic radionuclide rhenium-188 that could deliver high absorbed doses to tumours without exceeding kidney and bone marrow toxicity limits [12].